Target Audience

This program is designed for hematologists/oncologists, dermatologists, researchers, physician assistants, nurses and students.

Learning Objectives

After participating in this activity, you should be able to:

  • Describe new surveillance techniques and follow-up of patients with early melanoma using the latest technologies.
  • State the role of complete node dissections for microscopic nodal disease based on current evidence that assesses the clinical utility of sentinel node mapping in the management of malignant melanoma.
  • Compare the advantages and limitations of intralesional, locoregional and systemic interventions for treatment of advanced cutaneous malignancies.
  • Assess unique clinical situations such as brain metastases, giant congenital nevi, and desmoplastic melanoma and determine appropriate treatment approaches.
  • Examine recent evidence about basal cell carcinomas and hedgehog inhibition, and the management of cutaneous t-cell lymphomas and aggressive squamous cell carcinomas.
  • Review potential benefits and adverse effects of emerging therapeutic agents for the treatment of primary cutaneous malignancies.
  • Obtain an understanding of the role of currently available and potential future applications of immunotherapy and targeted therapy for advanced melanoma.
  • Analyze outcomes from investigative clinical trials that involve the use of adjuvant therapy and novel biologics for the treatment of high risk melanoma.
  • Determine how to best utilize the various biomarkers and correlate with outcome to optimize care for patients with melanoma.
  • Evaluate the potential positive impact that interdisciplinary approaches to melanoma treatment may have on patient outcomes.
  • Analyze potential algorithms for the treatment of advanced melanomas, using newly approved agents, to assist in therapeutic decision making.
This continuing medical education activity is provided by

HemOnc Today Melanoma 2015 is supported, in part, by educational grants from Bristol-Myers Squibb; Merck & Co., Inc.; Prometheus Laboratories; and Provectus Biopharmaceuticals, Inc.

HemOnc Today Melanoma 2015 is sponsored, in part, by Amgen; Genentech, Inc; and Provectus Biopharmaceuticals, Inc.

ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: For the purpose of recertifying with the ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.